Pfizer appoints Albert Bourla to newly-created role of COO
Pfizer has announced the appointment of Albert Bourla to the newly-created role of chief operating officer with effect from 1 January, 2018.
Dow Jones I.A.
38,239.66
04:30 15/10/20
Pfizer Inc.
$25.40
11:04 26/04/24
Chairman and chief executive officer Ian Read said: “The naming of a chief operating officer comes at a time when our business is strong as we continue to advance our strategy while also managing a dynamic and challenging external environment.
"The addition of a COO will enable me to spend more time focusing on the company's long term strategic direction, ensuring continued R&D productivity and engaging with government policy and industry leaders on key issues facing the future of the healthcare industry.”
Bourla has been the President of Pfizer’s Innovative Health Business since the beginning of 2016. Under his leadership, revenues for the division grew 11% operationally in 2016 and were up 9% in the first nine months of 2017.
Prior to his current role, Bourla was the group president for Pfizer’s Vaccines, Oncology and Consumer Healthcare businesses, during which time the company said he was instrumental in building a strong and competitive position in Oncology and expanding the group’s leadership in vaccines.
Effective 1 January, John Young, group president of Essential Health will become group president of Pfizer Innovative Health, while Angela Hwang, global president and general manager for Pfizer Inflammation & Immunology will succeed Young.
At 1550 GMT, the shares were up 0.1% to $35.22.